These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 2895853

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ceftazidime alone for treating Pseudomonas aeruginosa septicaemia in neutropenic patients.
    Verhagen C, de Pauw BE, Donnelly JP, Williams KJ, de Witte T, Janssen TH.
    J Infect; 1986 Sep; 13(2):125-31. PubMed ID: 3093589
    [Abstract] [Full Text] [Related]

  • 3. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure.
    Pea F, Viale P, Damiani D, Pavan F, Cristini F, Fanin R, Furlanut M.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3550-3. PubMed ID: 16048982
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Use of ceftazidime in the treatment of skin infections].
    Carabelli A, Tinozzi CC.
    G Ital Dermatol Venereol; 1986 Aug; 121(6):LXXIII-LXXV. PubMed ID: 3549545
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Pharmacodynamic optimization of ceftazidime against Pseudomonas aeruginosa: continuous infusion or intermittent administration?].
    Aguilar L, Giménez MJ, Martín JE, Prieto J.
    Rev Esp Quimioter; 2005 Mar; 18(1):21-5. PubMed ID: 15915228
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)].
    Guy H, Caillot D, Solary E, Bielefeld P, Portier H, Kazmierczak A.
    Presse Med; 1987 Dec 16; 16(43):2172-5. PubMed ID: 2963306
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Indications for systemic antibiotic prophylaxis in neutropenic patients.
    Spiers AS, Tattersall MH, Gaya H.
    Br Med J; 1974 Nov 23; 4(5942):440-1. PubMed ID: 4214579
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nosocomial infectious balanoposthitis in neutropenic patients.
    Manian FA, Alford RH.
    South Med J; 1987 Jul 23; 80(7):909-11. PubMed ID: 3110971
    [Abstract] [Full Text] [Related]

  • 17. [Infections in neutropenic children with neoplasms. Case series contribution].
    Giacchino M, Artino RM, Miniero R, Grazia G, Vivalda M, Dotti G, Mattirolo F, Madon E.
    Minerva Pediatr; 1988 Jun 23; 40(6):339-44. PubMed ID: 3054471
    [No Abstract] [Full Text] [Related]

  • 18. Ceftazidime in patients with Pseudomonas infections.
    Eron LJ, Park CH, Hixon DL, Goldenberg RI, Poretz DM.
    J Antimicrob Chemother; 1983 Jul 23; 12 Suppl A():161-9. PubMed ID: 6225762
    [Abstract] [Full Text] [Related]

  • 19. Outcomes of hospitalized neutropenic oncology patients with Pseudomonas aeruginosa bloodstream infections: focus on oral fluoroquinolone conversion.
    Yan LZ, Herrington JD.
    J Oncol Pharm Pract; 2016 Aug 23; 22(4):584-90. PubMed ID: 26156260
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.